3D bioprinted GelMA scaffolds for clinical applications: Promise and challenges

Q1 Computer Science

Bioprinting Pub Date : 2024-10-19 DOI:10.1016/j.bprint.2024.e00365

Soumitra Das, Remya Valoor, Jeyapriya Thimukonda Jegadeesan, Bikramjit Basu

{"title":"3D bioprinted GelMA scaffolds for clinical applications: Promise and challenges","authors":"Soumitra Das, Remya Valoor, Jeyapriya Thimukonda Jegadeesan, Bikramjit Basu","doi":"10.1016/j.bprint.2024.e00365","DOIUrl":null,"url":null,"abstract":"<div><div>The promise of bioprinting in diverse applications ranging from <em>in vitro</em> drug screening to creating patient-specific tissues/organs for personalized medicine has attracted significant attention globally. In this context, this review discusses the progress being made over the last decades with gelatin methacryloyl (GelMA) as a foundational hydrogel for diverse bioprintable ink formulations in particular relevance to printability, buildability, and bio-functionality. Furthermore, a comprehensive analysis is presented on the recent developments in 3D (bio)printing of GelMA for the reconstruction or regeneration of artificial tissues, spanning musculoskeletal, neurological, cardiovascular, urological, ophthalmological, dermatological, and drug screening of cancer-related applications. While presenting such wide-ranging potential, an emphasis is placed on addressing the key challenges associated with scaling up from small-scale laboratory practices to clinical applications. Furthermore, the review sheds light on the regulatory framework-related issues that impede the widespread clinical usage of 3D bioprinted tissues and organs in patient care. Taken together, this review provides significant insights into the current state of the field for researchers, clinicians, and policymakers, while navigating the intricate landscape of 3D (bio)printing for clinical translation.</div></div>","PeriodicalId":37770,"journal":{"name":"Bioprinting","volume":"44 ","pages":"Article e00365"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioprinting","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S240588662400037X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Computer Science","Score":null,"Total":0}

引用次数: 0

Abstract

The promise of bioprinting in diverse applications ranging from in vitro drug screening to creating patient-specific tissues/organs for personalized medicine has attracted significant attention globally. In this context, this review discusses the progress being made over the last decades with gelatin methacryloyl (GelMA) as a foundational hydrogel for diverse bioprintable ink formulations in particular relevance to printability, buildability, and bio-functionality. Furthermore, a comprehensive analysis is presented on the recent developments in 3D (bio)printing of GelMA for the reconstruction or regeneration of artificial tissues, spanning musculoskeletal, neurological, cardiovascular, urological, ophthalmological, dermatological, and drug screening of cancer-related applications. While presenting such wide-ranging potential, an emphasis is placed on addressing the key challenges associated with scaling up from small-scale laboratory practices to clinical applications. Furthermore, the review sheds light on the regulatory framework-related issues that impede the widespread clinical usage of 3D bioprinted tissues and organs in patient care. Taken together, this review provides significant insights into the current state of the field for researchers, clinicians, and policymakers, while navigating the intricate landscape of 3D (bio)printing for clinical translation.

查看原文本刊更多论文

用于临床应用的三维生物打印凝胶MA支架：前景与挑战

从体外药物筛选到为个性化医疗创建患者特异性组织/器官，生物打印在各种应用领域的前景引起了全球的广泛关注。在此背景下，本综述讨论了过去几十年来甲基丙烯酰明胶（GelMA）作为各种生物打印墨水配方的基础水凝胶所取得的进展，特别是在可打印性、可构建性和生物功能性方面。此外，本文还全面分析了三维（生物）打印 GelMA 用于人工组织重建或再生的最新进展，其应用领域涵盖肌肉骨骼、神经、心血管、泌尿、眼科、皮肤以及癌症相关的药物筛选。在展示如此广泛的潜力的同时，还着重探讨了从小规模实验室实践到临床应用的关键挑战。此外，本综述还揭示了与监管框架相关的问题，这些问题阻碍了三维生物打印组织和器官在患者护理中的广泛临床应用。综上所述，本综述为研究人员、临床医生和政策制定者提供了有关该领域现状的重要见解，同时也为三维（生物）打印在临床转化中的复杂应用提供了导航。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bioprinting Computer Science-Computer Science Applications

CiteScore

11.50

自引率

0.00%

发文量

审稿时长

68 days

期刊介绍： Bioprinting is a broad-spectrum, multidisciplinary journal that covers all aspects of 3D fabrication technology involving biological tissues, organs and cells for medical and biotechnology applications. Topics covered include nanomaterials, biomaterials, scaffolds, 3D printing technology, imaging and CAD/CAM software and hardware, post-printing bioreactor maturation, cell and biological factor patterning, biofabrication, tissue engineering and other applications of 3D bioprinting technology. Bioprinting publishes research reports describing novel results with high clinical significance in all areas of 3D bioprinting research. Bioprinting issues contain a wide variety of review and analysis articles covering topics relevant to 3D bioprinting ranging from basic biological, material and technical advances to pre-clinical and clinical applications of 3D bioprinting.